CVKD Cadrenal Therapeutics, Inc.
$1.09▼ -7.63%
Healthcare
Other
After hours
$1.07▼ -1.65%
Sep 11, 7:09 PM ET
Volume 228.0K
Avg Volume (10D) 2.36M
Key Metrics & Fundamentals
Market Cap
$3.89M
P/E Ratio
–
Div Yield
–%
52W Range
1.00 - 14.64
% vs 50 MA
-44.62%
% vs 200 MA
-79.35%
RSI-14
22.8
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.99
Free Cash Flow
-$2.23M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.34M
COGS
–
Operating Exp
$3.34M
Operating Income
-$3.34M
EBIT
-$3.34M
Pretax Income
-$3.32M
Net Income
-$3.32M
EPS (Diluted)
-1.14
Price & Volume History
Loading chart…
Recent News
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
GlobeNewswire · Sep 3, 2026 12:00 PM
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
GlobeNewswire · Aug 31, 2026 12:00 PM
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
Zacks Small Cap Research · Aug 31, 2026 11:03 AM
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
GlobeNewswire · Aug 13, 2026 8:15 PM
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
Zacks Small Cap Research · Aug 3, 2026 4:15 PM
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
GlobeNewswire · Aug 3, 2026 12:30 PM
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
GlobeNewswire · Jul 21, 2026 12:00 PM
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
GlobeNewswire · Jul 13, 2026 1:00 PM
Cadrenal Therapeutics Prices Private Placement for Up to $8.8 Million
MT Newswires · Jul 1, 2026 7:55 AM
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire · Jul 1, 2026 12:00 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CVKD's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.